Compare LSE & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSE | ESLA |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 69.5M |
| IPO Year | N/A | N/A |
| Metric | LSE | ESLA |
|---|---|---|
| Price | $4.73 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 6.3K | ★ 28.7K |
| Earning Date | 01-30-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $61.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $0.78 |
| 52 Week High | $9.78 | $3.15 |
| Indicator | LSE | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 44.15 | 36.98 |
| Support Level | $4.45 | $0.97 |
| Resistance Level | $4.95 | $1.35 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 33.44 | 15.62 |
Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment, oil and gas engineering technical services, new energy production and operation, and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment, which supplies various equipment, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.